Novo Nordisk holds 29 patents protecting semaglutide (Ozempic/Wegovy/Rybelsus) in the U.S., with key patents expiring as late as 2033
From improved urinary control to enhanced sexual function, learn how EMSELLA delivers visible results in six sessionswith no downtime and no medications
People are suing Novo Nordisk and Eli Lilly and Company due to legal issues surrounding their GLP-1 receptor agonist drugs, with plaintiffs bringing forth substantially similar allegations against both drug manufacturers
Do not assume your current access to compounded semaglutide will last indefinitely
You can inject into your abdomen, thigh, or upper armrotating injection sites prevents skin irritation and lipohypertrophy over months of treatment
These medications have not been reviewed by the FDA for safety, efficacy, or quality